The development and commercialisation of innovative treatments for central nervous system (CNS) disorders have proved yet again not to be for the faint hearted. While we are seeing encouraging progress across Asia Pacific (APAC) and beyond, for example, advances in understanding the complex biology of these conditions, the identification of new drug targets or a raft of novel late-stage candidates for treating serious CNS disorders progressing through the development pipeline and entering the market, CNS innovators have suffered numerous, high-profile setbacks, including Aduhelm as one of the most prominent in recent history.
info@wilam.comAn initiative ofBioMelbourne NetworkLevel 6, HWT Tower40 City RoadSouthbank, VIC 3006
Wilam means home in the Woi-wurrung language of the Wurundjeri People of the Kulin Nation, the Traditional Owners of the lands on which we are based.We respectfully acknowledge the Traditional Custodians of the unceded lands and waters of Victoria, the Bunurong, Eastern Maar, Gunaikurnai, Wadawurrung and Wurundjeri Woi-wurrung peoples, on which we live and work. We pay respect to their Elders past and present. We acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector. We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.